查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198698

尿失禁设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Urinary Incontinence Treatment Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 122 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计 2021 年尿失禁治疗设备市场价值 33.9292 亿美元，预测期内復合年增长率为 6.6%。

多个国家在 2020 年 COVID-19 大流行初期进入封锁状态。由于与其他国家的贸易暂停和旅行限制，2020 年上半年诊断和手术有所下降。

根据British Journal of Surgery 2020 年 5 月发表的一项研究，假设因 COVID-19 大流行导致医院服务中断 12 週的高峰期，2020 年全球将有大约 2840 万例择期手术被取消或推迟。此外，根据国际财团 2020 年 5 月进行的一项研究，由于 COVID-19 流行病，印度有超过 580,000 例择期手术被取消或推迟。

促进市场增长的一个主要因素是尿失禁 (UI) 患病率的上升。许多因素会导致尿失禁的发生，包括尿路感染、盆底肌和尿道括约肌减弱、更年期、怀孕、分娩和男性根治性前列腺切除术后。在 2021 年 6 月发表的题为 "Prevalence of Urinary Incontinence among Young Healthy Females in Gujarat-A Cross-sectional Study" 的研究中，经过 2017 年 12 月至 2018 年 10 月为期 11 个月的调查期后，尿失禁在年龄较大的健康年轻女性中的患病率18-25岁人群占71.85%，其中压力型尿失禁占50.85%，急迫型占9.16%，混合型占40%。

美国国家生物技术信息中心（NCBI）发表的一篇题为《绝经后妇女尿失禁（2019）》的论文发现，帕金森病、糖尿病、多发性硬化症等多种疾病的发病率都在增加，而且无论男女两者都被认为会增加尿失禁的患病率。因此，预计在预测期内对尿失禁治疗设备的需求将会增加。此外，对微创手术的需求不断增长和技术不断进步也有望推动市场增长。增加 UI 领域的研发正在提高公众意识并探索市场机会，这有望推动市场增长。

此外，市场参与者正在采取各种策略，如产品发布、开发、收购、合併和合作伙伴关係，以扩大其在所研究市场中的产品组合，这正在推动市场的增长。例如，2019年11月，Renovia Inc.宣布了下一代leva Pelvic Digital Therapeutic，用于增强盆底肌肉，治疗女性压力性/混合性尿失禁和轻度至中度紧急尿失禁（UI）。宣布获得美国食品和药物管理局 (FDA) 的 510(k) 批准。

然而，诸如缺乏对疾病设备和社会耻辱的认识以及与程序相关的风险和并发症等因素预计将阻碍预测期内的市场增长。

尿失禁治疗设备的市场趋势

预计尿道吊带部分将在预测期内实现健康增长

由于尿道吊带被强烈推荐作为治疗压力性尿失禁的手术方法，因此尿道吊带部分有望出现增长。

2020 年 8 月发表的一项题为 "A Global Survey on the Impact of COVID-19 on Urological Services" 的研究发现，尿失禁、良性前列腺增生、不孕不育和性门诊的内科、肾结石、阴囊良性疾病和膀胱结石受影响最大。此外，2020年疫情期间，各类门诊检查和手续全线下降。特别是，针对女性尿失禁、不孕症、肾结石和膀胱结石的外科手术服务减少最多。这些对该部门的增长产生了负面影响。

尿道吊带手术也称为尿道中部吊带手术。所用的吊带材料可以是取自雌性、猪等动物的肌肉、韧带和肌腱组织。它们也可以由合成材料製成，例如与身体组织相容的塑料或随时间分解的可吸收聚合物。

根据 2021 年 2 月发表的文章《女性尿失禁很常见但可以治疗》，尿失禁是不受控制的尿液漏出，从几滴到完全意外不等。50 岁以上的女性中，近二分之一正在处理问题与尿失禁有关。文章还指出，超过 2500 万美国人经常承认有膀胱控制问题。女性尿失禁率上升和人口老龄化增加了对尿道吊带手术的需求。

此外，由于手术后恢復快，患者对它的需求量很大。除了吊带手术带来的低风险和益处外，对微创手术不断增长的需求也推动了这一领域的增长。

波士顿科学公司于 2019 年 2 月重新设计并推出了 Mesh Sling System，这是一种用于男性患者压力性尿失禁的外科植入物。这种手术网也被植入以支撑尿道颈，以纠正压力性尿失禁 (SUI)。

此外，尿失禁量的增加和尿失禁治疗研究的积累是尿道吊带领域增长的主要因素。

预计在预测期内，北美将占据重要的市场份额

推动北美地区市场增长的主要因素包括尿失禁 (UI) 患病率的增加、老年人口的增加以及该地区对微创手术的需求。

由于 COVID-19 大流行，泌尿外科平台市场参与者的收入下降。例如，康乐保公司的介入泌尿科部门在 2019-20 财年实现了负有机增长（-7%）。这种负增长主要是由于 Altis 单切口吊带等产品的销量下降，其次是 COVID-19 爆发后美国取消了选择性手术和程序。由于 COVID-19 流行病，美国以外的国家也推迟了择期手术。

儘管受到其他因素的大流行的负面影响，但研究的市场显示北美地区的增长。根据加拿大政府统计报告，截至2019年7月，加拿大老年人口为6,592,611人，占加拿大总人口的17.5%。随着时间的推移，加拿大老年人口的比例一直在增加。人口老龄化的出现对加拿大尿失禁设备市场产生了积极影响，因为膀胱控制问题、尿漏和尿失禁等膀胱疾病的风险随着年龄的增长而增加。

根据 2021 年 6 月发表在 Medscape 上的一篇文章“尿失禁的患病率是多少？”，估计 UI 在美国影响了 10-13 百万人。此外，仅在美国，治疗 UI 的费用就达 163 亿美元，其中 75% 花在了女性身上。因此，UI 在美国的流行率正在上升，预计这将推动市场的增长。

主要参与者为加强市场地位而采取的研发、併购和产品发布等战略也是推动所研究市场增长的因素。2020 年 2 月，Atlantic Therapeutics 获得美国食品和药物管理局（FDA）批准 INNOVO，这是一种经临床验证的非侵入性可穿戴设备，用于治疗成年女性压力性尿失禁（SUI）。宣布已授予超过-柜檯销售许可。因此，预计这些因素将在预测期内推动该地区的尿失禁治疗设备市场。

尿失禁设备市场的竞争对手分析

尿失禁治疗设备市场竞争激烈。目前主导市场的公司包括 Boston Scientific Corporation、Becton、Dickinson and Company、Coloplast Corp.、Promedon Group、AMI GmbH、Johnson & Johnson、Zephyr Surgical Implants、Medtronic PLC、Caldera Medical Inc.、Hollister Incorporated、Nipro Corporation、Karl Storz SE & Co.KG、B Braun Melsungen AG、Baxter International Inc.、ConvaTec Group PLC 等。

其他福利

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

目录

第 1 章 简介

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第三章执行摘要

第四章市场动态

  • 市场概况
  • 市场驱动力
    • 尿失禁患病率上升和人口老龄化
    • 对微创手术和产品开发的需求不断增长
  • 市场製约因素
    • 关于尿失禁的低意识和社会耻辱感
    • 手术风险和并发症
  • 波特五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争对手之间的竞争

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品
    • 尿道吊带
    • 电刺激器
    • 人工尿道括约肌
    • 导尿管，其他
  • 按最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 欧洲其他地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太其他地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 中东其他地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美地区

第六章公司概况及竞争格局

  • 公司简介
    • Boston Scientific Corporation
    • BD
    • Colopast Group
    • PROMEDON GmbH
    • AMI GmbH
    • Johnson & Johnson（Ethicon）
    • Zephyr Surgical Implants
    • Medtronic
    • Caldera Medical Inc.
    • Hollister Incorporated
    • KARL STORZ SE & Co. KG
    • B Braun Melsungen AG
    • ConvaTec Group PLC

第七章市场机会与未来趋势

简介目录
Product Code: 68593

The urinary incontinence treatment devices market was valued at USD 3392.92 million in 2021 and is expected to record a CAGR of 6.6% during the forecast period.

In the initial days of the COVID-19 pandemic in 2020, several countries were in lockdown. Suspension in trade with other countries and travel restrictions led to a decline in diagnosis and surgical procedures in the first half of 2020.

According to a study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption for hospital services due to the COVID-19 pandemic, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, more than 580,000 planned surgeries in India were canceled or delayed because of the COVID-19 pandemic, according to a study conducted by an international consortium in May 2020.

The major factor contributing to the market's growth is the rising prevalence of urinary incontinence (UI). Numerous factors such as urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in men lead to the development of urinary incontinence symptoms. A study titled "Prevalence of Urinary Incontinence among Young Healthy Females in Gujarat - A Cross-sectional Study," published in June 2021, found that after the study period of 11 months from December 2017 to October 2018, among the total population, the prevalence of UI was 71.85% among young women who were healthy and aged between 18-25 years, of whom 50.85% had stress, 9.16% had urge, and 40% had a mixed type of urinary incontinence.

An article titled "Urinary Incontinence in Postmenopausal Women (2019)," published in the National Center for Biotechnology Information (NCBI), found that there has been a rise in the incidence of various diseases, such as Parkinson's disease, diabetes, multiple sclerosis, etc., which may lead to increased prevalence of urinary incontinence in males and females. This is expected to boost demand for urinary incontinence treatment devices over the forecast period. Furthermore, the growing demand for minimally invasive procedures and increasing technological advancements are expected to boost market growth. Increasing research and development in the field of UI is creating awareness among people and opportunities in the market studied, which is expected to propel the market's growth.

Moreover, market players are adopting various strategies, such as product launches, developments, acquisitions, mergers, and collaborations, to expand their product portfolio in the market studied, which is boosting the market growth. For instance, in November 2019, Renovia Inc. announced the US Food and Drug Administration's (FDA) 510(k) clearance for its next-generation leva Pelvic Digital Therapeutic, which will be used for strengthening pelvic floor muscles and for the treatment of stress and mixed and mild to moderate urgency urinary incontinence (UI) in women.

However, factors such as a lack of awareness about devices and social stigma associated with the disease, and the risks and complications related to the procedures, are expected to impede market growth over the forecast period.

Urinary Incontinence Treatment Devices Market Trends

Urethral Slings Segment Expected to Witness Healthy Growth over the Forecast Period

The urethral slings segment is expected to witness growth as these are highly recommended for surgical treatment for the treatment of stress urinary incontinence.

A study entitled "A Global Survey on the Impact of COVID-19 on Urological Services," published in August 2020, showed that during the COVID-19 pandemic, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, sexual medicine, renal stone, benign scrotal conditions, and bladder stone were the most affected, among others. Besides, there was a decline across various types of outpatient investigations and procedures during the outbreak in 2020. Particularly surgical procedures for female urinary incontinence, infertility, renal stones, and bladder stones had the highest rates of decline in services. These affected the growth of the segment negatively.

Urethral slings surgery is also known as mid-urethral sling surgery. The sling material used may be muscle, ligament, or tendon tissue taken from the woman or an animal, such as a pig. It may also be composed of synthetic material, such as plastic compatible with body tissues or absorbable polymer that disintegrates over time.

According to an article published in February 2021, titled "Urinary Incontinence in Women Common, but Treatable," urinary incontinence is the unconditional loss of urine, which can be a few drops of leakage to a full accident and almost 1 in 2 women over the age of 50 years deal with issues related to urinary incontinence. This article also mentioned that more than 25 million Americans admit that they regularly face issues controlling their bladders. The rising prevalence of urinary incontinence among women and the aging population is boosting the demand for urethral sling surgery.

Furthermore, the quick recovery time of procedures is increasing its demand among the patient population. Apart from the low risk rates and advantages offered by sling procedures, the increasing demand for minimally invasive surgeries is also boosting the segment's growth.

Boston Scientific launched a redesign of its mesh sling system in February 2019, which is a surgical implant for stress urinary incontinence in male patients. The surgical mesh is also implanted to support the urethra neck to correct stress urinary incontinence (SUI).

Moreover, the growing volume of urinary incontinence and cumulative research in urinary incontinence treatment are the major factors for the growth of the urethral slings segment.

North America Expected to Hold a Significant Market Share over the Forecast Period

The major factors driving the market growth in the North American region are increases in the prevalence of urinary incontinence (UI), the geriatric population, and the demand for minimally invasive surgeries in the region.

Urology platform market players suffered a decline in revenues due to the COVID-19 pandemic. For instance, the interventional urology segment of Coloplast Corp. generated negative organic growth (-7%) in the financial year 2019-20. The negative growth was mainly due to a decrease in sales of Altis single-incision slings and other products, followed by the cancellation of elective surgeries and procedures in the US after the COVID-19 outbreak. Elective procedures outside the US were also postponed in several countries during the COVID-19 outbreak.

The market studied has shown growth in the North American region despite the negative impact of the pandemic owing to other factors. As of July 2019, the Canadian geriatric population included 6,592,611 people, which accounted for 17.5% of the Canadian population, as per the Government of Canada's statistics report. The proportion of senior citizens in Canada has been increasing with time. As aging increases the risk of bladder problems such as bladder control issues, and leakage or urinary incontinence, thus, the increasing aging population is positively influencing the Canadian urinary incontinence treatment devices market.

As per the article published in Medscape in June 2021, titled, "What is the prevalence of urinary incontinence?," it was estimated that UI would affect 10-13 million people in the US. Additionally, the cost of treatment of UI in the US alone is USD 16.3 billion, 75% of which is spent on the treatment of women. This increasing prevalence of UI in the US is expected to propel the market's growth.

Strategies adopted by major companies, such as research and development, mergers and acquisitions, and product launches to strengthen their market position are another driving factor for the growth of the market studied. In February 2020, Atlantic Therapeutics announced that the US Food and Drug Administration (FDA) had granted over-the-counter (OTC) clearance to INNOVO, a non-invasive, clinically proven, and wearable device for the treatment of stress urinary incontinence (SUI) in adult females. Therefore, these aforementioned factors are expected to boost the urinary incontinence treatment devices market in the region over the forecast period.

Urinary Incontinence Treatment Devices Market Competitor Analysis

The urinary incontinence treatment devices market is moderately competitive. Some of the companies currently dominating the market are Boston Scientific Corporation, Becton, Dickinson and Company, Coloplast Corp., Promedon Group, AMI GmbH, Johnson & Johnson, Zephyr Surgical Implants, Medtronic PLC, Caldera Medical Inc., Hollister Incorporated, Nipro Corporation, Karl Storz SE & Co. KG, B Braun Melsungen AG, Baxter International Inc., and ConvaTec Group PLC, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric Population
    • 4.2.2 Rise in Demand for Minimally Invasive Surgery and Product Development
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness about Devices and Social Stigma Associated with the Disease
    • 4.3.2 Risks and Complications from the Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Urethral Slings
    • 5.1.2 Electrical Stimulation Devices
    • 5.1.3 Artificial Urinary Sphincters
    • 5.1.4 Catheters and Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPANY PROFILES AND COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 BD
    • 6.1.3 Colopast Group
    • 6.1.4 PROMEDON GmbH
    • 6.1.5 AMI GmbH
    • 6.1.6 Johnson & Johnson (Ethicon)
    • 6.1.7 Zephyr Surgical Implants
    • 6.1.8 Medtronic
    • 6.1.9 Caldera Medical Inc.
    • 6.1.10 Hollister Incorporated
    • 6.1.11 KARL STORZ SE & Co. KG
    • 6.1.12 B Braun Melsungen AG
    • 6.1.13 ConvaTec Group PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS